Mayo Clinic

Anumana is a technology company that specializes in developing artificial intelligence algorithms to analyze electrocardiogram (ECG) data, facilitating early diagnosis of cardiovascular conditions. By leveraging advanced machine learning techniques, Anumana's platform enhances cardiac care, providing healthcare professionals with tools to identify potential heart issues efficiently. The company's focus extends beyond diagnostics to improve patient outcomes across the entire continuum of cardiovascular care, including perioperative and acute settings. Through its innovative approach, Anumana aims to refine screening processes, enabling clinicians to detect heart diseases earlier and intervene more effectively, ultimately contributing to improved healthcare delivery and management of cardiovascular health.

Myosin Therapeutics is a privately-held biopharmaceutical company dedicated to developing innovative medications for central nervous system (CNS) disorders and other significant unmet medical needs. The company specializes in harnessing molecular machines that convert energy into mechanical work within cells. This technology enables targeted treatment of various disease states, including cancer, by focusing on cellular motor proteins. Through its research and development efforts, Myosin Therapeutics aims to address critical challenges in disease management and improve patient outcomes.

Delfina is a company that specializes in developing a personalized prenatal care system aimed at ensuring the safety of mothers and infants during pregnancy. By leveraging data and machine learning, Delfina's platform creates individualized pregnancy care plans that assess patient risk through various metrics. This approach not only enhances interventional workflows but also improves provider efficiency, facilitating early intervention in prenatal care. Delfina's commitment to data-driven insights is paving the way for clinical innovation, ultimately striving to deliver equitable and cost-effective healthcare solutions for expectant families.

Jupiter Bioventures is a venture builder company dedicated to de-risking early-stage therapeutic projects. It operates by evaluating opportunities through a specific set of investment criteria and providing initial seed capital to founders. This approach enables the growth of innovative projects in the biotechnology sector, supporting entrepreneurs as they navigate the challenges of early development. By focusing on early-stage initiatives, Jupiter Bioventures aims to foster advancements in therapeutic solutions while minimizing the inherent risks associated with new ventures.

Aignostics GmbH is a Berlin-based company founded in 2018 that specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics, employing patented technology to reverse-engineer conventional AI systems, thereby addressing their “black-box” limitations. Aignostics' platform generates explainable diagnostic results presented as precise heatmaps and image overlays, which facilitate the verification process for pathologists. This capability is crucial in ensuring accurate diagnoses, particularly in the context of discovering and validating biomarkers for cancer and other complex diseases. By improving the understanding of tissue-based biomarkers, Aignostics aims to significantly advance the diagnosis and treatment of various conditions, thereby supporting the broader goals of precision medicine and drug development.

Endogenex is a medical technology company founded in 2017, focused on developing innovative solutions for patients with type 2 diabetes. The company has created an endoscopic procedure that employs pulsed electric fields to regenerate the duodenal mucosa, aiming to enhance glycemic control in individuals suffering from this condition. By providing a novel therapy, Endogenex seeks to empower patients to better manage their blood glucose levels and improve their overall health outcomes.

Qlaris Bio, Inc. is a clinical-stage biotechnology company based in Wellesley, Massachusetts, focused on developing innovative therapies for serious ophthalmic diseases. Founded in 2017, the company is working on QLS-101, a therapy aimed at reducing intraocular pressure, a critical factor in conditions such as glaucoma. Qlaris Bio explores novel mechanisms to address episcleral venous pressure, which significantly contributes to intraocular pressure, thereby aiming to mitigate the risk of blindness associated with both Primary Open Angle Glaucoma and Normal Tension Glaucoma. The company also targets high unmet medical needs in pediatric rare diseases related to intraocular pressure disturbances, where effective treatment options are currently limited.

UpDoc is a technology-enabled services firm that offers the world's first unique conversational AI platform for autonomous prescription management.

Abridge Inc. is a healthcare technology company founded in September 1999, focused on enhancing communication in medical settings through innovative tools. The company utilizes generative AI to automate the transcription and summarization of patient-clinician conversations, converting these interactions into structured clinical notes in real-time. This platform integrates seamlessly with Electronic Health Record (EHR) systems, significantly reducing the need for manual note-taking. By generating clear and understandable summaries, Abridge improves patient comprehension of medical discussions and ensures that relevant documentation is accurately recorded in patient files. Additionally, the company emphasizes data security and patient privacy, adhering to healthcare regulations while providing a customizable interface that caters to individual patient needs.

Nucleus RadioPharma is a company focused on enhancing the accessibility of radiopharmaceuticals for cancer patients. It specializes in developing innovative technologies aimed at modernizing the clinical development, manufacturing, and supply chain processes associated with radiopharmaceutical therapies. By streamlining these aspects, Nucleus RadioPharma seeks to improve the delivery of novel treatments, thereby enabling healthcare professionals to more effectively diagnose and treat various cancer diseases.

EBAMed SA is a Swiss startup based in Geneva that specializes in developing innovative medical devices for the non-invasive treatment of heart arrhythmias. Founded in 2018, the company focuses on creating an ultrasound-based device that utilizes proton therapy to monitor heart motion and synchronize therapeutic beams in real time. This technology allows for the precise delivery of radiation treatment to targeted heart tissues, thereby expanding treatment options for existing proton therapy centers and enabling them to treat heart patients effectively. By providing a non-invasive approach to cardiac care, EBAMed aims to improve patient outcomes and streamline treatment processes in outpatient settings.

AccurKardia is an ECG-led diagnostics software company dedicated to enhancing the utility of ECG data as a diagnostic tool and biomarker to improve patient outcomes globally. The company specializes in cloud-based diagnostic solutions, including AccurECG™, an FDA-cleared software that provides fully automated, near real-time ECG interpretation. Additionally, AccurKardia developed AK+ Guard™, an AI-driven solution designed to detect hyperkalemia using Lead I ECG data, which aids patients with chronic kidney disease and end-stage renal disease in identifying dangerously high potassium levels at an earlier stage; this product has received FDA Breakthrough Device Designation. The company's aortic stenosis detection model, AK-AVS™, also received similar recognition. AccurKardia participated in the 2024 Cohort of MedTech Innovator and was selected for the inaugural American Heart Association's Heart and Brain Health Accelerator track, further emphasizing its commitment to advancing cardiac diagnostics and monitoring.

Medivis manufactures Software as a Medical Device (SaMD) for augmented reality surgical navigation. The company was founded in 2016 and is headquartered in the Flatiron district of New York City.

Lucem Health is a company that specializes in remote diagnostics through an innovative platform that connects patient telemetry and biosensing devices with artificial intelligence algorithms. The platform is designed to facilitate data ingestion, orchestration, and connectivity, which enhances continuous care for patients while allowing them greater control over their health. Additionally, Lucem Health supports the development and deployment of clinical AI models, enabling healthcare providers to integrate AI-generated insights into their workflows. This capability allows clinicians to improve care delivery by better understanding the impact of these insights on patient outcomes. Overall, Lucem Health aims to enhance the effectiveness of healthcare through advanced technology and data-driven solutions.

Mediwhale is a health diagnostics company that focuses on leveraging artificial intelligence to enhance the prevention of cardiovascular and kidney diseases. It operates a unique AI screening platform that assesses metabolic risks and diagnoses eye diseases through non-invasive retinal scans. The platform comprises several components, including RetiCVD for cardiovascular disease risk assessment, which utilizes coronary artery calcium scores to predict risks based on established guidelines. RetiCKD offers a chronic kidney disease risk assessment with improved predictive capabilities compared to traditional methods. Additionally, RetiEYE identifies common age-related eye diseases like diabetic retinopathy and glaucoma at their referable stages. Mediwhale's retinal-based systemic biomarkers have been clinically validated and are recognized in the medical community, supported by publications in reputable journals. Through its innovative approach, Mediwhale aims to establish a sustainable healthcare model that emphasizes early detection and intervention.

R-Zero specializes in biosafety technology aimed at minimizing the impact of viruses in indoor environments. The company develops products that enhance the disinfection of everyday spaces, utilizing mobile UV-C units that effectively sanitize large areas quickly and efficiently. In addition to its disinfection solutions, R-Zero offers smart building technologies that provide real-time insights for optimizing indoor spaces. These solutions focus on improving workforce productivity, predicting real estate needs, and creating operational efficiencies, such as lowering energy costs. R-Zero's platform includes features like indoor air quality monitoring, high-efficiency HVAC filtration, space utilization sensors, and occupancy-based building controls, ensuring that building owners and operators can prepare their facilities for future challenges. The technology is designed to be user-friendly, secure, and scalable, making it accessible for a variety of users.

Acorai is a medical device company focused on developing a non-invasive heart failure monitoring platform that centers around direct intracardiac pressure monitoring (ICPM). The company utilizes a unique combination of sensor technologies and machine learning to enable accurate and cost-effective heart failure management. Acorai's technology allows for the non-invasive monitoring of cardiac and pulmonary pressure through the analysis of acoustic, vibratory, and waveform data, making it the only proven method to enhance outcomes for heart failure patients. The device has received clinical validation and has been designated as an FDA Breakthrough Device, with plans to enter the market in 2025. By enabling healthcare professionals to proactively adjust medications, Acorai aims to reduce both the rates of heart failure re-hospitalization and mortality.

Nucleus RadioPharma is a company focused on enhancing the accessibility of radiopharmaceuticals for cancer patients. It specializes in developing innovative technologies aimed at modernizing the clinical development, manufacturing, and supply chain processes associated with radiopharmaceutical therapies. By streamlining these aspects, Nucleus RadioPharma seeks to improve the delivery of novel treatments, thereby enabling healthcare professionals to more effectively diagnose and treat various cancer diseases.

Senda Biosciences, founded in 2017 in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company investigates the molecular relationships among bacterial, botanical, and human cells, aiming to understand how these interactions influence health and disease. By leveraging insights from these interspecies connections, Senda Biosciences seeks to create new categories of medicines and delivery methods that can assist medical professionals in providing effective treatments.

Diagnostic Robotics Ltd is an Israeli company, founded in 2017 and headquartered in Tel Aviv, that specializes in developing artificial intelligence solutions for the healthcare sector. The company offers a signal-agnostic AI system designed to assist healthcare insurers, providers, and patients by creating predictive analytics models. These models aim to address significant clinical and financial challenges faced by the healthcare industry, ultimately optimizing clinical program performance and improving return on investment. By enabling healthcare systems to deliver more effective care at reduced costs, Diagnostic Robotics facilitates informed decision-making and proactive interventions in patient care.

Karkinos Healthcare is technology-driven oncology focussed managed health care platform for the early detection and diagnosis of common cancers.

Vyriad, Inc. is a clinical-stage biotechnology company focused on developing targeted cancer therapies through the use of engineered viruses. These therapies, which include oncolytic immunovirotherapy products derived from oncolytic vesicular stomatitis virus and oncolytic measles virus platforms, are designed to selectively target and destroy cancer cells while sparing normal tissues. Vyriad's innovative approach aims to not only treat cancer but also to stimulate immune responses that can prevent recurrence. Additionally, the company is engaged in creating diagnostic and theranostic tests to accurately predict patient responses to its immunovirotherapy treatments. Vyriad's foundational research is supported by collaboration with prominent institutions such as the Mayo Clinic and the University of Miami. Established in 2012, Vyriad is headquartered in Rochester, Minnesota.

Theator Inc. is a company that specializes in developing a surgical intelligence platform designed to enhance surgeon performance through the use of artificial intelligence and computer vision. Founded in 2018 and based in San Mateo, California, Theator offers a product known as Minutes, which includes content management software and a visual operative report with analytics. This platform analyzes and houses video data from surgical procedures, allowing surgeons to review and learn from past surgeries for educational purposes. By extracting and annotating key moments from real-world procedures, Theator empowers surgeons to gain insights into their performance and fosters a culture of continuous improvement in the operating room. The company's partnerships with innovative surgeons and hospitals aim to create a more transparent surgical environment while elevating surgical expertise.

Tympany Medical is a company focused on advancing minimally invasive ear surgeries through innovative technology. It has developed a specialized ear surgery device that facilitates sterile endoscopy in the field of otolaryngology. This device addresses the challenges associated with traditional endoscopes, enhancing usability and flexibility for surgeons. By enabling effective endoscopic visualization, Tympany's technology allows surgeons to perform complex ear procedures while preserving their two-handed operating technique. The company's mission is to reduce the need for unnecessary mastoidectomies and improve surgical outcomes for patients undergoing ear surgery.

SimBioSys is focused on advancing cancer care through its innovative Computational Microscope, which merges advanced simulation techniques with a wide array of experimental datasets. This technology enables researchers to gain insights into the cancer microenvironment, allowing them to observe tumor behavior, including cell phenotypes and interactions with surrounding tissues. By creating personalized virtual tumors from comprehensive diagnostic data, SimBioSys facilitates computational scenario analysis that enhances doctors' understanding of individual cases. This approach aims to improve decision-making and patient experiences in the realm of oncology, ultimately transforming cancer treatment.

Laplace Interventional is a medical device company specializing in the development of transcatheter tricuspid valve technology. This innovative technology aims to enhance life expectancy and improve the quality of life for patients suffering from tricuspid regurgitation. The company's prosthetic valve is delivered through a minimally invasive procedure, eliminating the need for open-heart surgery. By offering a less invasive treatment option, Laplace Interventional enables healthcare providers to mitigate future complications for patients, thereby contributing to a better overall health outcome.

R-Zero specializes in biosafety technology aimed at minimizing the impact of viruses in indoor environments. The company develops products that enhance the disinfection of everyday spaces, utilizing mobile UV-C units that effectively sanitize large areas quickly and efficiently. In addition to its disinfection solutions, R-Zero offers smart building technologies that provide real-time insights for optimizing indoor spaces. These solutions focus on improving workforce productivity, predicting real estate needs, and creating operational efficiencies, such as lowering energy costs. R-Zero's platform includes features like indoor air quality monitoring, high-efficiency HVAC filtration, space utilization sensors, and occupancy-based building controls, ensuring that building owners and operators can prepare their facilities for future challenges. The technology is designed to be user-friendly, secure, and scalable, making it accessible for a variety of users.

Senda Biosciences, founded in 2017 in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company investigates the molecular relationships among bacterial, botanical, and human cells, aiming to understand how these interactions influence health and disease. By leveraging insights from these interspecies connections, Senda Biosciences seeks to create new categories of medicines and delivery methods that can assist medical professionals in providing effective treatments.

Helix is a prominent population genomics company that focuses on integrating genomic data into clinical care, research, and public health. Its comprehensive platform facilitates large-scale genetic analysis and actionable insights, serving health systems, life sciences companies, payers, and government organizations. Helix operates one of the largest CLIA and CAP-certified next-generation sequencing laboratories and employs its proprietary Exome+™ assay to support various aspects of population genomics. This includes recruitment and engagement, clinically actionable disease screening, and the return of results, as well as basic and translational research. By advancing genomic research and enhancing patient care, Helix plays a critical role in shaping healthcare through genetics.

Anumana is a technology company that specializes in developing artificial intelligence algorithms to analyze electrocardiogram (ECG) data, facilitating early diagnosis of cardiovascular conditions. By leveraging advanced machine learning techniques, Anumana's platform enhances cardiac care, providing healthcare professionals with tools to identify potential heart issues efficiently. The company's focus extends beyond diagnostics to improve patient outcomes across the entire continuum of cardiovascular care, including perioperative and acute settings. Through its innovative approach, Anumana aims to refine screening processes, enabling clinicians to detect heart diseases earlier and intervene more effectively, ultimately contributing to improved healthcare delivery and management of cardiovascular health.

Anumana is a technology company that specializes in developing artificial intelligence algorithms to analyze electrocardiogram (ECG) data, facilitating early diagnosis of cardiovascular conditions. By leveraging advanced machine learning techniques, Anumana's platform enhances cardiac care, providing healthcare professionals with tools to identify potential heart issues efficiently. The company's focus extends beyond diagnostics to improve patient outcomes across the entire continuum of cardiovascular care, including perioperative and acute settings. Through its innovative approach, Anumana aims to refine screening processes, enabling clinicians to detect heart diseases earlier and intervene more effectively, ultimately contributing to improved healthcare delivery and management of cardiovascular health.

Diagnostic Robotics Ltd is an Israeli company, founded in 2017 and headquartered in Tel Aviv, that specializes in developing artificial intelligence solutions for the healthcare sector. The company offers a signal-agnostic AI system designed to assist healthcare insurers, providers, and patients by creating predictive analytics models. These models aim to address significant clinical and financial challenges faced by the healthcare industry, ultimately optimizing clinical program performance and improving return on investment. By enabling healthcare systems to deliver more effective care at reduced costs, Diagnostic Robotics facilitates informed decision-making and proactive interventions in patient care.

nference, Inc. is a biotechnology company that specializes in an AI-based software platform designed to synthesize and analyze biomedical information. Founded in 2013 and headquartered in Cambridge, Massachusetts, with additional offices in Bengaluru, Toronto, and Rochester, nference focuses on transforming unstructured and structured data from biomedical literature, electronic medical records, and real-world datasets. The company's technology utilizes neural networks to automate the extraction of insights from diverse datasets, facilitating advancements in drug discovery, life cycle management, and precision medicine. By providing comprehensive biological and clinical insights, nference aims to support pharmaceutical, biotechnology, and healthcare enterprises in overcoming challenges in drug development and clinical research, ultimately enabling the discovery of personalized diagnostics and treatments for patients.

Progentec Diagnostics, Inc. is focused on developing advanced diagnostic tests aimed at improving the management of systemic lupus erythematosus (SLE). The company's flagship platform, aiSLE DX, offers tools such as a flare prediction score, which proactively measures disease activity, and an early diagnosis test for lupus. Established in 2015 and headquartered in Oklahoma City, Oklahoma, Progentec collaborates with various research institutions and experts globally to leverage innovations in diagnostics. The company is dedicated to addressing significant unmet needs in healthcare by enhancing disease management through improved diagnostic capabilities, ultimately aiming to facilitate early detection and reduce disease incidence.

nference, Inc. is a biotechnology company that specializes in an AI-based software platform designed to synthesize and analyze biomedical information. Founded in 2013 and headquartered in Cambridge, Massachusetts, with additional offices in Bengaluru, Toronto, and Rochester, nference focuses on transforming unstructured and structured data from biomedical literature, electronic medical records, and real-world datasets. The company's technology utilizes neural networks to automate the extraction of insights from diverse datasets, facilitating advancements in drug discovery, life cycle management, and precision medicine. By providing comprehensive biological and clinical insights, nference aims to support pharmaceutical, biotechnology, and healthcare enterprises in overcoming challenges in drug development and clinical research, ultimately enabling the discovery of personalized diagnostics and treatments for patients.

Novome Biotechnologies, Inc. is a biotechnology company specializing in the engineering of gut bacteria to create innovative therapies for chronic diseases. Established in 2015 and located in South San Francisco, California, Novome has developed a pioneering platform for the controlled colonization of the gut with genetically engineered microbial medicines (GEMMs). This platform allows for the precise delivery of therapeutic activities aimed at treating conditions such as hyperoxaluria, with a focus on creating a bacterial strain that can degrade oxalate to help prevent kidney stone formation. The company is also expanding its synthetic biology capabilities to explore additional therapeutic indications, aiming to improve long-term health outcomes for patients through its living therapeutics.

HuidaGene Therapeutics Co., Ltd. is a biotechnology company based in Shanghai, China, founded in 2018. The company specializes in the research and development of gene therapies for single-gene disorders and is expanding its focus to neurodegenerative diseases and vision disorders. HuidaGene employs its proprietary CRISPR-based and AI-driven HG-PRECISE platform to create potentially curative therapies. Among its clinical programs, HuidaGene is advancing HG004 for RPE65-associated retinal disease, HG202 for neovascular age-related macular degeneration, HG204 for MECP2 duplication syndrome, and HG302 for Duchenne muscular dystrophy. Several of these therapies have received orphan drug designations and rare pediatric disease designations from regulatory authorities. In addition to its clinical initiatives, the company is exploring preclinical programs, including HG303 for amyotrophic lateral sclerosis and a CRISPR RNA-editing therapy for Alzheimer’s disease.

NewCompliance is a healthcare technology company focused on enhancing the quality and safety of medical care through innovative solutions. The company collaborates with industry leaders such as Stryker, Medtronic, Skytron, and Philips to provide interoperable IT platforms. Its flagship product, the ACTIQ platform, delivers predictive dashboarding and analytics, offering real-time feedback and intelligent management information to healthcare providers. This web-based software is designed to support caregivers across various departments, including surgery, emergency care, and intensive care. By optimizing safety, efficiency, and patient satisfaction, NewCompliance aims to transform the surgical patient journey and improve overall healthcare delivery.

FundamentalVR have been working with leading pharmaceutical companies to combine virtual and mixed reality with haptic feedback using their ‘FeelRealVR’ platform to create simulated surgical procedures to help educate and train healthcare professionals. The company works at the nexus of haptics, machine learning, and immersive technologies (XR). FundamentalVR was established in 2012 by Chris Scattergood in London, England.

AtriAN Medical is an Irish medical device company based in Galway, a prominent center for medical technology innovation. The company is focused on commercializing advanced technology developed at the Mayo Clinic in the United States. AtriAN specializes in a medical device designed to treat atrial fibrillation by employing micro Pulsed Electric Fields (mPEF). This innovative approach selectively ablates hyperactive tissue while preserving surrounding myocardium, minimizing damage to the heart muscle. Utilizing a catheter, AtriAN's device delivers short pulses of electrical energy directly to the problematic areas, offering a targeted treatment option that enhances patient safety and outcomes.

Qlaris Bio, Inc. is a clinical-stage biotechnology company based in Wellesley, Massachusetts, focused on developing innovative therapies for serious ophthalmic diseases. Founded in 2017, the company is working on QLS-101, a therapy aimed at reducing intraocular pressure, a critical factor in conditions such as glaucoma. Qlaris Bio explores novel mechanisms to address episcleral venous pressure, which significantly contributes to intraocular pressure, thereby aiming to mitigate the risk of blindness associated with both Primary Open Angle Glaucoma and Normal Tension Glaucoma. The company also targets high unmet medical needs in pediatric rare diseases related to intraocular pressure disturbances, where effective treatment options are currently limited.

GYANT is a digital front door solution for health systems that leverages artificial intelligence to enhance patient navigation to appropriate care settings and in-network resources. The company's platform utilizes natural language processing to understand patients' needs, guiding them throughout their healthcare encounters. By streamlining digital patient journeys, GYANT aims to capture new patients and efficiently serve existing ones while driving process automation within healthcare enterprises. This innovative approach not only improves patient engagement but also enhances care utilization, ultimately leading to reduced costs and time savings for healthcare providers.

Pendulum Therapeutics Inc. is a microbiome-focused company based in San Francisco that specializes in developing medical probiotics and prebiotics aimed at managing chronic illnesses, particularly type 2 diabetes. The company's flagship product, Pendulum Glucose Control, was introduced in 2020 and has demonstrated effectiveness in lowering blood sugar spikes and reducing A1C levels, as evidenced by published clinical trials. Pendulum utilizes evidence-based microbiome science and DNA sequencing to create targeted interventions, allowing clinicians to identify specific microbiome markers for disease treatment. Founded in 2013, Pendulum holds 13 patents and has 42 pending, with significant backing from prominent investors. The company sells its products online, focusing on improving healthcare through innovative microbiome therapies.

Giblib is a California-based company founded in 2015 and headquartered in Los Angeles. It operates an online video community platform that serves as a resource for medical education, akin to a streaming service for surgical knowledge. The platform allows surgeons to share and access a curated collection of surgical videos and medical lectures across various specialties. By indexing surgical procedures and creating educational content, Giblib provides medical students and practitioners with valuable insights into surgical techniques and medical practices from experienced professionals.

StemoniX Inc. is a biotechnology company that specializes in stem cell technologies aimed at advancing drug discovery and personalized medicine. Founded in 2014 and headquartered in Minneapolis, Minnesota, with an additional office in La Jolla, California, StemoniX offers a proprietary platform that facilitates the creation and scaling of human tissue derived from stem cells. This platform supports the 3-D printing of living cells for various applications, including research into heart disease, dementia, breast cancer, autism, and ALS. By operationalizing human-induced pluripotent stem cell (iPSC) disease models at scale, StemoniX enhances the efficiency of neurotoxicity research and drug screening, enabling scientists to conduct more effective studies with improved outcomes.

Caraway Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on developing innovative treatments for neurodegenerative diseases by modulating mitophagy and autophagy. The company aims to address the degradation of toxic cellular components, which is a key factor in various neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis. By leveraging an understanding of critical neural pathways, Caraway Therapeutics seeks to discover and develop novel small molecules that can restore cellular balance and improve lysosomal function. Founded in 2018 and initially known as Rheostat Therapeutics, Inc., the company rebranded in 2019 to reflect its commitment to finding effective therapies for patients affected by these debilitating diseases.

Ambient Clinical Analytics, Inc. is a healthcare technology company specializing in data assimilation, communication, and analytics for clinical decision support. Based in Rochester, Minnesota, the company develops tools tailored for use in intensive care units, operating rooms, and emergency departments. Its flagship product, AWARE, integrates with various electronic health record systems and bedside monitors to deliver critical patient information on a unified dashboard. Additionally, Ambient offers the Mayo Clinic YES Board, a multi-patient management tool that enhances situational awareness and streamlines patient flow. The company also provides specialized solutions such as Sepsis DART for real-time sepsis detection and the Ventilator-Induced Lung Injury Sniffer for monitoring ventilator patients. Furthermore, the Synthesis Platform serves as an integration hub for AWARE and the Mayo Clinic tools, facilitating seamless data exchange. Ambient Clinical Analytics was founded in 2013 and focuses on improving patient outcomes while reducing healthcare costs through innovative technology.

Geneticure Inc. is a pharmacogenetic testing company based in Eden Prairie, Minnesota, founded in 2012. The company specializes in developing tools and tests that enable clinicians to deliver personalized medicine, particularly for patients with hypertension. Utilizing a patented cheek-swab test, Geneticure predicts individual responses to high blood pressure medications and therapies. The process includes DNA extraction and genotyping, providing healthcare providers with genetic results, a summary for each gene, and a decision tree prioritizing gene functionality. These insights help clinicians optimize blood pressure therapy tailored to each patient's unique genetic makeup. By offering at-home testing options, Geneticure aims to make the management of blood pressure more accessible and effective for patients. The company is backed by the Mayo Clinic, reinforcing its commitment to evidence-based approaches in personalized medicine.

Unity Biotechnology, Inc. is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span by addressing age-related diseases. The company specializes in clearing senescent cells through the creation of senolytic medicines, which specifically target vulnerabilities unique to these cells while sparing healthy ones. Its lead drug candidates include UBX0101, currently in Phase II clinical trials for musculoskeletal conditions like osteoarthritis, and UBX1325, which is in Phase I trials for diabetic macular edema. Additionally, Unity is developing treatments for various conditions related to aging, including pulmonary and neurological disorders, as well as kidney and liver diseases. Founded in 2009 and headquartered in South San Francisco, California, Unity Biotechnology was previously known as Forge, Inc. before changing its name in 2015.

Helix is a prominent population genomics company that focuses on integrating genomic data into clinical care, research, and public health. Its comprehensive platform facilitates large-scale genetic analysis and actionable insights, serving health systems, life sciences companies, payers, and government organizations. Helix operates one of the largest CLIA and CAP-certified next-generation sequencing laboratories and employs its proprietary Exome+™ assay to support various aspects of population genomics. This includes recruitment and engagement, clinically actionable disease screening, and the return of results, as well as basic and translational research. By advancing genomic research and enhancing patient care, Helix plays a critical role in shaping healthcare through genetics.

Helixis, Inc. is a company that develops low-cost molecular diagnostic products.

Progentec Diagnostics, Inc. is focused on developing advanced diagnostic tests aimed at improving the management of systemic lupus erythematosus (SLE). The company's flagship platform, aiSLE DX, offers tools such as a flare prediction score, which proactively measures disease activity, and an early diagnosis test for lupus. Established in 2015 and headquartered in Oklahoma City, Oklahoma, Progentec collaborates with various research institutions and experts globally to leverage innovations in diagnostics. The company is dedicated to addressing significant unmet needs in healthcare by enhancing disease management through improved diagnostic capabilities, ultimately aiming to facilitate early detection and reduce disease incidence.

Unity Biotechnology, Inc. is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span by addressing age-related diseases. The company specializes in clearing senescent cells through the creation of senolytic medicines, which specifically target vulnerabilities unique to these cells while sparing healthy ones. Its lead drug candidates include UBX0101, currently in Phase II clinical trials for musculoskeletal conditions like osteoarthritis, and UBX1325, which is in Phase I trials for diabetic macular edema. Additionally, Unity is developing treatments for various conditions related to aging, including pulmonary and neurological disorders, as well as kidney and liver diseases. Founded in 2009 and headquartered in South San Francisco, California, Unity Biotechnology was previously known as Forge, Inc. before changing its name in 2015.

DayTwo Ltd. is a precision nutrition company based in Tel Aviv-Yafo, Israel, that focuses on leveraging gut microbiome analysis to provide tailored health solutions for metabolic diseases such as diabetes, prediabetes, clinical obesity, and non-alcoholic fatty liver disease (NAFLD). Founded in 2015, DayTwo utilizes a web-based platform that offers personalized dietary recommendations through its innovative Food Prescriptions™, which are designed to help individuals manage their blood sugar levels and improve overall health. By sequencing gut microbiomes, the company identifies how different foods affect each person, allowing for customized nutrition plans. DayTwo's virtual care model is supported by Certified Diabetes Care and Education Specialists and Registered Dietitians, who engage with patients through a smartphone application to track progress and ensure adherence to the dietary recommendations.

Unity Biotechnology, Inc. is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span by addressing age-related diseases. The company specializes in clearing senescent cells through the creation of senolytic medicines, which specifically target vulnerabilities unique to these cells while sparing healthy ones. Its lead drug candidates include UBX0101, currently in Phase II clinical trials for musculoskeletal conditions like osteoarthritis, and UBX1325, which is in Phase I trials for diabetic macular edema. Additionally, Unity is developing treatments for various conditions related to aging, including pulmonary and neurological disorders, as well as kidney and liver diseases. Founded in 2009 and headquartered in South San Francisco, California, Unity Biotechnology was previously known as Forge, Inc. before changing its name in 2015.

Chrono Therapeutics Inc. is a pharmaceutical company based in Hayward, California, focused on revolutionizing drug delivery and addiction management. Founded in 2003, the company specializes in the development of SmartStop, a digital nicotine replacement therapy that employs a wearable device to deliver programmable, transdermal drug therapy. This innovative system is designed to tailor the timing and dosage of nicotine while providing real-time behavioral support to help users manage addiction and smoking cessation effectively. Chrono Therapeutics aims to address the challenges associated with smoking addiction through its advanced technology, which seeks to achieve optimal clinical outcomes and improve the overall quality of life for users. The company's leadership team brings extensive experience in product development, research and development, and navigating regulatory pathways, positioning Chrono Therapeutics as a key player in the smoking cessation market.

Torax Medical, Inc. is a clinical stage medical device company based in Shoreview, Minnesota, founded in 2002. The company specializes in developing and marketing innovative products aimed at restoring the barrier function of sphincters, primarily for the treatment of gastroesophageal reflux disease (GERD) and fecal incontinence. Its flagship product, the LINX reflux management system, utilizes specialized magnets to provide a minimally invasive solution for patients suffering from GERD. Additionally, Torax offers the FENIX continence restoration system, designed to address fecal incontinence. The company's products are available in both the United States and Europe, reflecting its commitment to improving patient outcomes in the field of digestive diseases. Torax Medical operates as a subsidiary of Ethicon, Inc.

Epirium Bio, Inc. is a biopharmaceutical company based in San Diego, California, focused on developing therapeutics for cardiovascular diseases, metabolic syndrome, and disorders characterized by mitochondrial dysfunction. Founded in 2008, the company leverages unique insights into mitochondrial biology and tissue regeneration to create a small molecule platform aimed at improving muscle strength and facilitating tissue regeneration. Epirium Bio's innovative approach addresses significant clinical needs in treating neuromuscular, neurodegenerative, and mitochondrial disorders, enabling healthcare providers to better support patients suffering from conditions such as muscular dystrophy.

Helix is a prominent population genomics company that focuses on integrating genomic data into clinical care, research, and public health. Its comprehensive platform facilitates large-scale genetic analysis and actionable insights, serving health systems, life sciences companies, payers, and government organizations. Helix operates one of the largest CLIA and CAP-certified next-generation sequencing laboratories and employs its proprietary Exome+™ assay to support various aspects of population genomics. This includes recruitment and engagement, clinically actionable disease screening, and the return of results, as well as basic and translational research. By advancing genomic research and enhancing patient care, Helix plays a critical role in shaping healthcare through genetics.

Lifecode, Inc. is a molecular diagnostics company based in Foster City, California, specializing in next-generation sequencing (NGS) technology. The company develops a range of NGS-based cancer assays, including its flagship product, the Lifecode Pan Cancer Somatic Panel, which is designed for use in various metastatic and rare cancers, as well as for patients seeking clinical trials. Lifecode focuses on translating complex genomic and therapeutic data into actionable insights for healthcare providers, patients, and payers. The company's team comprises experts in data science, software engineering, computational biology, bioinformatics, machine learning, molecular biology, and pathology, enabling it to bridge the gap between advanced sequencing technology and clinical application. Lifecode was previously known as Silicon Valley Biosystems, Inc. and rebranded in 2015. As of early 2016, it operates as a subsidiary of MedGenome Labs Private Ltd.

Unity Biotechnology, Inc. is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span by addressing age-related diseases. The company specializes in clearing senescent cells through the creation of senolytic medicines, which specifically target vulnerabilities unique to these cells while sparing healthy ones. Its lead drug candidates include UBX0101, currently in Phase II clinical trials for musculoskeletal conditions like osteoarthritis, and UBX1325, which is in Phase I trials for diabetic macular edema. Additionally, Unity is developing treatments for various conditions related to aging, including pulmonary and neurological disorders, as well as kidney and liver diseases. Founded in 2009 and headquartered in South San Francisco, California, Unity Biotechnology was previously known as Forge, Inc. before changing its name in 2015.

Assurex Health is a personalized medicine company based in Mason, Ohio, that specializes in pharmacogenomics. The company is dedicated to assisting healthcare providers in identifying the most suitable medications for individual patients with various medical conditions, including neuropsychiatric disorders and chronic pain. By offering treatment decision support, Assurex Health empowers clinicians to collect and analyze genetic information, thereby enhancing the precision of medication selection tailored to each patient's unique genetic makeup.

Ambra Health is a medical data and image management company that provides a cloud-based platform designed to enhance the accessibility and management of medical images. The platform is intuitive, flexible, and scalable, enabling healthcare providers, including prominent health systems and clinical research organizations, to improve their imaging workflows and collaborative care. By offering secure and straightforward access to medical images, Ambra Health facilitates better internal adoption and collaboration among healthcare professionals. This capability allows organizations to significantly enhance their operational efficiency and patient care outcomes by making medical images and data accessible from anywhere.

Chrono Therapeutics Inc. is a pharmaceutical company based in Hayward, California, focused on revolutionizing drug delivery and addiction management. Founded in 2003, the company specializes in the development of SmartStop, a digital nicotine replacement therapy that employs a wearable device to deliver programmable, transdermal drug therapy. This innovative system is designed to tailor the timing and dosage of nicotine while providing real-time behavioral support to help users manage addiction and smoking cessation effectively. Chrono Therapeutics aims to address the challenges associated with smoking addiction through its advanced technology, which seeks to achieve optimal clinical outcomes and improve the overall quality of life for users. The company's leadership team brings extensive experience in product development, research and development, and navigating regulatory pathways, positioning Chrono Therapeutics as a key player in the smoking cessation market.

Pendulum Therapeutics Inc. is a microbiome-focused company based in San Francisco that specializes in developing medical probiotics and prebiotics aimed at managing chronic illnesses, particularly type 2 diabetes. The company's flagship product, Pendulum Glucose Control, was introduced in 2020 and has demonstrated effectiveness in lowering blood sugar spikes and reducing A1C levels, as evidenced by published clinical trials. Pendulum utilizes evidence-based microbiome science and DNA sequencing to create targeted interventions, allowing clinicians to identify specific microbiome markers for disease treatment. Founded in 2013, Pendulum holds 13 patents and has 42 pending, with significant backing from prominent investors. The company sells its products online, focusing on improving healthcare through innovative microbiome therapies.

Ambient Clinical Analytics, Inc. is a healthcare technology company specializing in data assimilation, communication, and analytics for clinical decision support. Based in Rochester, Minnesota, the company develops tools tailored for use in intensive care units, operating rooms, and emergency departments. Its flagship product, AWARE, integrates with various electronic health record systems and bedside monitors to deliver critical patient information on a unified dashboard. Additionally, Ambient offers the Mayo Clinic YES Board, a multi-patient management tool that enhances situational awareness and streamlines patient flow. The company also provides specialized solutions such as Sepsis DART for real-time sepsis detection and the Ventilator-Induced Lung Injury Sniffer for monitoring ventilator patients. Furthermore, the Synthesis Platform serves as an integration hub for AWARE and the Mayo Clinic tools, facilitating seamless data exchange. Ambient Clinical Analytics was founded in 2013 and focuses on improving patient outcomes while reducing healthcare costs through innovative technology.

Sanguine is a company focused on enhancing translational biomedical research by facilitating patient participation. It aims to bridge the gap between patients and researchers by offering personalized medicine solutions and a range of tools and concierge services. Sanguine empowers patients to engage in research from the comfort of their homes while ensuring transparency throughout the research process. The company's approach emphasizes respectful patient support and appropriate compensation, fostering a positive experience for participants and yielding more impactful biospecimens for research. Through its efforts, Sanguine seeks to improve the development of new treatments by actively involving patients in the medical research landscape.

Torax Medical, Inc. is a clinical stage medical device company based in Shoreview, Minnesota, founded in 2002. The company specializes in developing and marketing innovative products aimed at restoring the barrier function of sphincters, primarily for the treatment of gastroesophageal reflux disease (GERD) and fecal incontinence. Its flagship product, the LINX reflux management system, utilizes specialized magnets to provide a minimally invasive solution for patients suffering from GERD. Additionally, Torax offers the FENIX continence restoration system, designed to address fecal incontinence. The company's products are available in both the United States and Europe, reflecting its commitment to improving patient outcomes in the field of digestive diseases. Torax Medical operates as a subsidiary of Ethicon, Inc.

The Kang San Global Medical Technology (Beijing) Co., Ltd. is a hi-tech enterprise of one for the country at all levels of the hospital to provide advanced specialist inspection services, and the establishment of the National Laboratory of Kang Sheng Global Medical Special Inspection Center. Of the center's national service network belongs wholly owned ...

Anexon, Inc. is a pharmaceutical company located in Cambridge, Massachusetts, specializing in the development of therapeutics for cardiovascular diseases. The company focuses on biotechnology solutions, particularly an alternatively spliced variant of brain natriuretic peptide known as ANX-042. This innovative therapeutic aims to address the needs of patients suffering from chronic heart failure and kidney dysfunction. Through its research and development efforts, Anexon is dedicated to advancing treatment options in the cardiovascular space.

Torax Medical, Inc. is a clinical stage medical device company based in Shoreview, Minnesota, founded in 2002. The company specializes in developing and marketing innovative products aimed at restoring the barrier function of sphincters, primarily for the treatment of gastroesophageal reflux disease (GERD) and fecal incontinence. Its flagship product, the LINX reflux management system, utilizes specialized magnets to provide a minimally invasive solution for patients suffering from GERD. Additionally, Torax offers the FENIX continence restoration system, designed to address fecal incontinence. The company's products are available in both the United States and Europe, reflecting its commitment to improving patient outcomes in the field of digestive diseases. Torax Medical operates as a subsidiary of Ethicon, Inc.

Kardia Health Systems is a healthcare information technology firm offering the delivery of specialty medicine, starting with cardiology. Using Internet technology and a Software-as-a-Service (SaaS) business model, Kardia makes this technology accessible to practices of varying sizes. Kardia Health Systems, Inc. was incorporated in 2006 and is based in Golden Valley, Minnesota.

Kardia Health Systems is a healthcare information technology firm offering the delivery of specialty medicine, starting with cardiology. Using Internet technology and a Software-as-a-Service (SaaS) business model, Kardia makes this technology accessible to practices of varying sizes. Kardia Health Systems, Inc. was incorporated in 2006 and is based in Golden Valley, Minnesota.

Naviscan, Inc. is the leader in organ-specific molecular imaging. The company designs, manufactures, and distributes a high-resolution PET scanner which provides unprecedented visualization of small body parts. While Naviscan’s PET scanner can image virtually any body part that can fit into the gantry, it is most often utilized as an adjunct to conventional imaging technologies by clinicians who stage and manage breast cancer. Surgeons, radiologists, nuclear physicians, and oncologists in hospitals and breast clinics use our compact, mobile and easy-to-use PET scanner to precisely characterize breast cancer, enhance surgical planning, monitor patient response to therapy, and evaluate suspected recurrence.

Naviscan, Inc. is the leader in organ-specific molecular imaging. The company designs, manufactures, and distributes a high-resolution PET scanner which provides unprecedented visualization of small body parts. While Naviscan’s PET scanner can image virtually any body part that can fit into the gantry, it is most often utilized as an adjunct to conventional imaging technologies by clinicians who stage and manage breast cancer. Surgeons, radiologists, nuclear physicians, and oncologists in hospitals and breast clinics use our compact, mobile and easy-to-use PET scanner to precisely characterize breast cancer, enhance surgical planning, monitor patient response to therapy, and evaluate suspected recurrence.

Torax Medical, Inc. is a clinical stage medical device company based in Shoreview, Minnesota, founded in 2002. The company specializes in developing and marketing innovative products aimed at restoring the barrier function of sphincters, primarily for the treatment of gastroesophageal reflux disease (GERD) and fecal incontinence. Its flagship product, the LINX reflux management system, utilizes specialized magnets to provide a minimally invasive solution for patients suffering from GERD. Additionally, Torax offers the FENIX continence restoration system, designed to address fecal incontinence. The company's products are available in both the United States and Europe, reflecting its commitment to improving patient outcomes in the field of digestive diseases. Torax Medical operates as a subsidiary of Ethicon, Inc.